Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study

Yan Feng, Bruce G. Pollock, Kim Coley, Stephen Marder, Del Miller, Margaret Kirshner, Manickam Aravagiri, Lon Schneider, Robert R. Bies

Research output: Contribution to journalArticlepeer-review

69 Scopus citations


AIMS: To characterize pharmacokinetic (PK) variability of risperidone and 9-OH risperidone using sparse sampling and to evaluate the effect of covariates on PK parameters. METHODS: PK analysis used plasma samples collected from the Clinical Antipsychotic Trials of Intervention Effectiveness. A nonlinear mixed-effects model was developed using nonmem to describe simultaneously the risperidone and 9-OH risperidone concentration-time profile. Covariate effects on risperidone and 9-OH risperidone PK parameters were assessed, including age, weight, sex, smoking status, race and concomitant medications. RESULTS: PK samples comprised 1236 risperidone and 1236 9-OH risperidone concentrations from 490 subjects that were available for analysis. Ages ranged from 18 to 93 years. Population PK submodels for both risperidone and 9-OH risperidone with first-order absorption were selected to describe the concentration-time profile of risperidone and 9-OH risperidone. A mixture model was incorporated with risperidone clearance (CL) separately estimated for three subpopulations [poor metabolizer (PM), extensive metabolizer (EM) and intermediate metabolizer (IM)]. Age significantly affected 9-OH risperidone clearance. Population parameter estimates for CL in PM, IM and EM were 12.9, 36 and 65.4 l h-1 and parameter estimates for risperidone half-life in PM, IM and EM were 25, 8.5 and 4.7 h, respectively. CONCLUSIONS: A one-compartment mixture model with first-order absorption adequately described the risperidone and 9-OH risperidone concentrations. Age was identified as a significant covariate on 9-OH risperidone clearance in this study.

Original languageEnglish (US)
Pages (from-to)629-639
Number of pages11
JournalBritish Journal of Clinical Pharmacology
Issue number5
StatePublished - Nov 2008


  • CATIE trial
  • CYP2D6
  • Pharmacokinetics
  • Risperidone

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study'. Together they form a unique fingerprint.

Cite this